Terazosin

Compliance with the 1 mg initial dose must be strictly observed to minimise the potential for acute first-dose hypotensive episodes. Benign prostatic hyperplasia (BPH): initial 1 mg before bedtime (not to be exceeded as the initial dose), increased by approximately doubling at weekly or bi-weekly intervals to achieve the desired reduction in symptoms; maintenance is usually 5 to 10 mg once daily. Improvement in BPH symptoms may be detected as early as two weeks; there are at present insufficient data to suggest additional symptomatic relief with doses above 10 mg once daily. Treatment should be initiated using the Starter Pack and the response reviewed at four weeks. Transient side effects may occur at each titration step; if any side effects persist, consider reducing the dose. If administration is discontinued for more than several days, therapy should be re-instituted using the initial dose titration regimen. Elderly: no alteration in dosage recommendation is required. Hepatic impairment: titrate with particular caution (extensive hepatic metabolism, mainly biliary excretion); use is not recommended in severe hepatic impairment. Paediatric: not recommended for use in children — safety and efficacy in children have not been established. Caution with concomitant thiazides or other antihypertensives: if one is added during terazosin treatment the terazosin dose must be reduced or the drug discontinued and a new dose titration is essential (SPC section 4.4). SPC section 4.5 (interactions) was not captured in the fetched bundle — clinician to review.